Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Exelixis (EXEL)

Exelixis reports preliminary 2025 net product revenue of $2.123 billion and 2026 guidance

Positive Impact 3 of 5 earnings Written later

Exelixis said preliminary, unaudited fiscal 2025 net product revenue was about $2.123 billion and total revenue was about $2.320 billion. It also gave fiscal 2026 net product revenue guidance of $2.325 billion to $2.425 billion, which excludes any revenue from a potential zanzalintinib launch. The audit is ongoing, and final results are due February 10, 2026, so the figures could change.

Key points

  • Preliminary fiscal 2025 total revenues of about $2.320 billion and net product revenues of about $2.123 billion
  • Fiscal 2026 guidance: total revenues of $2.525 billion to $2.625 billion and net product revenues of $2.325 billion to $2.425 billion
  • Audited fiscal 2025 results are scheduled for release on February 10, 2026
  • An October 2025 buyback authorizes up to an additional $750 million of stock repurchases before December 31, 2026

The filing

CompanyExelixis (EXEL)
Form8-K, current report
Filed with the SECJan 12, 2026, 4:22 PM ET
Accession number0000939767-26-000003

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.